Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae | Zendy

William R. Wilson | Zendy; Ellen G Kline | Zendy; Chelsea E Jones | Zendy; Kristin Morder | Zendy; Roberta T. Mettus | Zendy; Yohei Doi | Zendy; M. Hong Nguyen | Zendy; Cornelius J. Clancy | Zendy; Ryan K. Shields | Zendy

Open Access

Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae

Author(s) -

William R. Wilson,

Ellen G Kline,

Chelsea E Jones,

Kristin Morder,

Roberta T. Mettus,

Yohei Doi,

M. Hong Nguyen,

Cornelius J. Clancy,

Ryan K. Shields

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02048-18

Subject(s) - carbapenem resistant enterobacteriaceae , ceftazidime/avibactam , enterobacteriaceae , microbiology and biotechnology , meropenem , biology , carbapenem , escherichia coli , genotype , porin , mutant , gene , antibiotics , genetics , antibiotic resistance , bacterial outer membrane

Meropenem-vaborbactam is a new agent with the potential to treat carbapenem-resistantEnterobacteriaceae (CRE) infections. We describe thein vitro activity of meropenem-vaborbactam against representative CRE genotypes and laboratory-engineeredEscherichia coli isolates harboring mutantbla KPC genes associated with ceftazidime-avibactam resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research